Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
EntheogeniX Biosciences gets going
Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy
Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience
Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses,
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that
GABA Therapeutics commences phase I study of Etifoxine
On Monday, GABA Therapeutics commenced dosing for its phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia.
EntheogeniX Biosciences gets going
Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy
Investors are eyeing psychedelics as the next big trend in healthcare as medical-grade treatments inch toward FDA approval
The investor base for companies creating psychedelic drugs can be categorized into three groups, Florian Brand of ATAI Life Sciences said: the visionaries, the “momentum investors,” and more recently, pharmaceutical and biotech investors.
ATAI, DemeRx pursue ‘neurochemical reset’ for addiction
ATAI Life Sciences and DemeRx are setting up a joint venture to develop a treatment for opioid dependence that works by giving people a “neurochemical reset.”
ATAI backs Neuronasal’s through-the-nose concussion treatment
Neuronasal is just the latest project for mental-health-focused ATAI. It has backed companies such as Compass Pathways, which is developing the psychedelic psilocybin, and Perception Neuroscience, which is working on a ketamine-like drug, both for the treatment of depression.
ATAI Life Sciences, Cyclica team up for mental health JV
Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new joint venture aimed at battling mental health.
Investors are eyeing psychedelics as the next big trend in healthcare as medical-grade treatments inch toward FDA approval
The investor base for companies creating psychedelic drugs can be categorized into three groups, Florian Brand of ATAI Life Sciences said: the visionaries, the “momentum investors,” and more recently, pharmaceutical and biotech investors.
Vast experience
and great access to deal flow
Strategy and investor relations
- Serial entrepreneur and investor
- Co-founder, Ribopharma (RNAi translation, today Alnylam, $10bn market cap)
- Raised $1.5bn+ over the last 20 years for portfolio companies
- Invests across the entire lifecycle of a company and has been involved in more than 40 successful IPOs and M&As
Executing drug development and operations
- Former interim CEO, Perception Neuroscience
- Former Co-founder and MD, Springlane
- Prior experience with Rocket Internet, Allianz, Tanzanian German Program to Support Health
- Background: Economics and management
Developing clinical strategy for lead compounds
- 26+ years of experience in various leadership roles in the biopharmaceutical industry
- Broad experience in various disease areas (e.g. CNS and cardiovascular)
- Background: Board-certified anesthesiologist and researcher in Heidelberg and Harvard
Innovation through flawless execution and cutting-edge data & technology
- 8 years of operations experience across product and commercial strategy (McKinsey, BCG, KPMG, Siemens)
- Leading experience in combining healthcare, data and (AI) technology (Google, DeepMind)
- Background: Management studies in the UK, France, Germany and Argentina
Finance leadership for early stage, pre-approval and established listed life sciences companies.
- 15+ years of experience covering all aspects of financial reporting and governance including acquisitions, divestments and integrations
- Background: International Corporate Finance across the US, UK, Europe, Middle East, Africa and Australia
Proven scientific leader and decision maker
- +10 years of experience across research, development, and regulatory strategy (Axial Biotherapeutics, Flex Pharma, Zalicus Inc., CombinatoRx Inc.)
- Demonstrated success in multiple aspects of R&D leadership including target selection, cross-functional R&D leadership, and regulatory program management.
- Background: Molecular biology and bioorganic chemistry
Supporting smooth communication and a high-performance team environment
- 10+ years of experience in Yoga and Mindfulness
- 7 years of Scientific Research in Life Sciences (Dr.rer.nat)
- Prior experience in team management, company organization and healthcare industry
- Background: Nutrition, genetics, molecular & cell biology
Communications and Business Development
- Led membership development at DC-based nonprofit working on advanced illness care issues and Medicare payment reform
- Experience in fundraising and communications for thought leaders
- Background: Economics, international affairs, and healthcare policy
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space